Ending one of the private insurance subsidies created by Obamacare to help more than 7 million people pay for their coverage would end up costing — not saving —the federal government money, according to an analysis from the nonpartisan Kaiser Family Foundation released Tuesday.

Health insurers pressed Trump administration officials on Tuesday to continue billions of dollars in subsidies for low-income people buying plans under the federal health care law, but left with nothing that would dissipate the fog of uncertainty hanging over the industry.

Congressional hearings. Federal investigations. Consumer outrage. In the wake of developments like these, many drug company executives are laying low. Their favored business models, based on raising drug prices indiscriminately, are now seen as a liability; many pharmaceutical companies are curbing increases on their products and accepting that this once-lucrative jig may be up.

More than two dozen doctors, pharmacists and business owners were charged Thursday in an alleged $40 million medical-insurance scam in Orange County and elsewhere that officials said “played with patients’ lives.”

As congressional Republicans’ efforts to repeal and replace the Affordable Care Act remain in limbo, the Trump administration and some states are taking steps to help insurers cover the cost of their sickest patients, a move that industry analysts say is critical to keeping premiums affordable for plans sold on the law’s online marketplaces in 2018.

Congressional negotiators on Tuesday inched toward a potential agreement on a catchall spending bill that would deny President Donald Trump’s request for immediate funding to construct a wall along the Mexico border. The emerging measure would increase the defense budget and eliminate the threat of a government shutdown on Trump’s 100th day in office this Saturday.